Source: Fortune
Summary
Isomorphic Labs, an AI drug discovery company, and Anduril, a defense tech company, have both raised significant funding, with Isomorphic announcing a $2.1 billion Series B and Anduril closing a $5 billion Series H at a $61 billion valuation. Both companies have been successful due to advances in AI, which have made previously impossible tasks possible. They are now at inflection points where results matter more than anything else. Isomorphic’s Demis Hassabis and Anduril’s Brian Schimpf both emphasize the importance of delivering results, whether it’s curing diseases or winning wars.
Our Reading
The numbers tell one story. Isomorphic and Anduril have both raised billions, but it’s not just about the money. Both companies are at a point where they need to deliver results. Hassabis says it’s about curing diseases, not just about the algorithm. Schimpf is building towards a future where Anduril’s success will be clear. The most gut-level versions of success are relatively binary – you either win or lose, you either cure diseases or you don’t. Anduril and Isomorphic are both isomorphic, two things that look different but have a lot in common.
Author: Evan Null
